LY-272,015

LY-272,015 is a β-carboline derivative drug developed by Eli Lilly, which acts as a potent and selective antagonist at the serotonin 5-HT_2B receptor. It has anti-hypertensive effects in animal models,^[1][2] and is also used in research into the other functions of the 5-HT_2B receptor.^[3]

LY-272,015

Clinical data
Other names	LY-272,015; 1-[(3,4-Dimethoxyphenyl)methy]-2,3,4,9-tetrahydro-6-methyl-1H-pyrido[3,4-b]indole
Identifiers
IUPAC name 1-(3,4-dimethoxybenzyl)-6-methyl-2,3,4,9-tetrahydro-1H-β-carboline
CAS Number	172895-15-7 Y
PubChem CID	9929424
ChemSpider	8105055
UNII	5NV3JP3GP6
CompTox Dashboard (EPA)	DTXSID701336801 DTXSID30432996, DTXSID701336801
Chemical and physical data
Formula	C21H24N2O2
Molar mass	336.435 g·mol−1
3D model (JSmol)	Interactive image
SMILES c4cc(C)cc3c4[nH]c2c3CCNC2Cc(cc1OC)ccc1OC
InChI InChI=1S/C21H24N2O2/c1-13-4-6-17-16(10-13)15-8-9-22-18(21(15)23-17)11-14-5-7-19(24-2)20(12-14)25-3/h4-7,10,12,18,22-23H,8-9,11H2,1-3H3 Key:GDAJGLDMCDMPIR-UHFFFAOYSA-N
(verify)

See also

• Substituted β-carboline
• Fenharmane